Patents by Inventor Sarah Rowell

Sarah Rowell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6512091
    Abstract: Specific BRCA1 mutations, PCR primers and hybridization probes are used in nucleic acid-based methods for diagnostic of inheritable breast cancer susceptibility. Additionally, binding agents, such as antibodies, specific for peptides encoded by the subject BRCA1 mutants are used to identify expression products of diagnostic mutations/rare alleles in patient derived fluid or tissue samples. Compositions with high binding affinity for transcription or translation products of the disclosed BRCA1 mutations and alleles are used in therapeutic intervention. Such products include anti-sense nucleic acids, peptides encoded by the subject nucleic acids, and binding agents such as antibodies, specific for such peptides.
    Type: Grant
    Filed: December 12, 1997
    Date of Patent: January 28, 2003
    Assignee: The Regents of the University of California
    Inventors: Mary-Claire King, Lori Friedman, Beth Ostermeyer, Sarah Rowell, Eric Lynch, Csilla Szabo, Ming Lee
  • Patent number: 5821328
    Abstract: Specific BRCA1 mutations, PCR primers and hybridization probes are used in nucleic acid-based methods for diagnostic of inheritable breast cancer susceptibility. Additionally, binding agents, such as antibodies, specific for peptides encoded by the subject BRCA1 mutants are used to identify expression products of diagnostic mutations/rare alleles in patient derived fluid or tissue samples. Compositions with high binding affinity for transcription or translation products of the disclosed BRCA1 mutations and alleles are used in therapeutic intervention. Such products include anti-sense nucleic acids, peptides encoded by the subject nucleic acids, and binding agents such as antibodies, specific for such peptides.
    Type: Grant
    Filed: April 2, 1997
    Date of Patent: October 13, 1998
    Assignee: The Regents of the University of California
    Inventors: Mary-Claire King, Lori Friedman, Beth Ostermeyer, Sarah Rowell, Eric Lynch, Csilla Szabo, Ming Lee
  • Patent number: 5622829
    Abstract: Specific BRCA1 mutations, PCR primers and hybridization probes are used in nucleic acid-based methods for diagnostic of inheritable breast cancer susceptibility. Additionally, binding agents, such as antibodies, specific for peptides encoded by the subject BRCA1 mutants are used to identify expression products of diagnostic mutations/rare alleles in patient derived fluid or tissue samples. Compositions with high binding affinity for transcription or translation products of the disclosed BRCA1 mutations and alleles are used in therapeutic intervention. Such products include anti-sense nucleic acids, peptides encoded by the subject nucleic acids, and binding agents such as antibodies, specific for such peptides.
    Type: Grant
    Filed: April 19, 1995
    Date of Patent: April 22, 1997
    Assignee: The Regents of the University of California
    Inventors: Mary-Claire King, Lori Friedman, Beth Ostermeyer, Sarah Rowell, Eric Lynch, Csilla Szabo, Ming Lee